0001708138-20-000118.txt : 20201231 0001708138-20-000118.hdr.sgml : 20201231 20201231173053 ACCESSION NUMBER: 0001708138-20-000118 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20201230 FILED AS OF DATE: 20201231 DATE AS OF CHANGE: 20201231 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: YANCOPOULOS GEORGE CENTRAL INDEX KEY: 0001226690 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-19034 FILM NUMBER: 201429533 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: REGENERON PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0000872589 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 133444607 STATE OF INCORPORATION: NY FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 777 OLD SAW MILL RIVER ROAD CITY: TARRYTOWN STATE: NY ZIP: 10591 BUSINESS PHONE: 9148477000 MAIL ADDRESS: STREET 1: 777 OLD SAW MILL RIVER ROAD CITY: TARRYTOWN STATE: NY ZIP: 10591 FORMER COMPANY: FORMER CONFORMED NAME: REGENERON PHARMACEUTICALS INC DATE OF NAME CHANGE: 19930328 4 1 edgardoc.xml PRIMARY DOCUMENT X0306 4 2020-12-30 0 0000872589 REGENERON PHARMACEUTICALS, INC. REGN 0001226690 YANCOPOULOS GEORGE 777 OLD SAW MILL RIVER ROAD TARRYTOWN NY 10591 1 1 0 0 President and Chief Scientific Common Stock 2020-12-30 4 M 0 240000 52.03 A 880938 D Common Stock 2020-12-30 4 F 0 130714 483.25 D 750224 D Common Stock 2020-12-30 4 M 0 158079 52.03 A 908303 D Common Stock 2020-12-30 4 F 0 86096 483.25 D 822207 D Common Stock 2020-07-27 5 G 0 57465 0.0 D 0 I by 2018 GRAT Common Stock 5821 I By 401(k) Plan Common Stock 376861 I by 2019 GRAT Non-Qualified Stock Option (right to buy) 52.03 2020-12-30 4 M 0 240000 0.0 D 2021-12-16 Common Stock 240000 158079 D Non-Qualified Stock Option (right to buy) 52.03 2020-12-30 4 M 0 158079 0.0 D 2021-12-16 Common Stock 158079 0 D With respect to 240,000 underlying shares (of which 0 remain outstanding), the option became exercisable on December 31, 2014, based upon the satisfaction by the company of certain performance criteria during the period ended December 31, 2014. With respect to 158,079 underlying shares (of which 0 remain outstanding), the stock option award vested in four equal annual installments, commencing one year after the date of grant. /s/**George D. Yancopoulos 2020-12-31